Recommended usage and dosage of seripalase (BRINEURA) and key matters to note when taking it

Seripase (BRINEURA) is a targeted enzyme replacement drug used to treat advanced Niemann-Pick disease typeC (CLN2 neurodegenerative disease) caused by neuronal cell sulfatase deficiency. Its core role is to slow down the process of neurodegeneration and improve patients' motor and cognitive functions by supplementing missing lysosomal enzymes. The drug is suitable for pediatric patients from 2 years old to 18 years old. It is currently an important clinical treatment option for CLN2 patients.

The recommended use of BRINEURA is intracerebroventricular injection (intracerebroventricular infusion), usually once every two weeks. Before administration, the patient's condition and weight must be assessed by a professional neurologist or pediatrician, and the injection must be performed with a ventricular catheter device (such as an Ommaya reservoir). The dosage of each injection should be calculated strictly according to the body weight and instructions to ensure that the enzyme concentration can not only exert the therapeutic effect but also reduce the risk of adverse reactions.

When taking it, you need to pay attention to several key things. First, the injection operation must be performed under strict sterile conditions to prevent infection; second, the patient's vital signs should be monitored before and after the injection, and attention should be paid to reactions such as fever, headache, or local infection. Clinical attention also needs to be paid to allergic or immune reactions, such as rashes, dyspnea, etc., and corresponding treatment and drug intervention are provided when necessary.

In addition, patients who use BRINEURA for a long time need to undergo regular follow-up, including neurological function evaluation, imaging examination and laboratory testing to ensure the efficacy and safety of the drug. Parents and caregivers should be familiar with the injection process and precautions to avoid risks caused by improper drug storage or operation. Through standardized medication and scientific monitoring, BRINEURA can play a positive role in delaying the CLN2 neurodegenerative process while ensuring the safety of medication for pediatric patients.

Reference materials:https://www.drugs.com/